Literature DB >> 35396962

Exploring the links among inflammation and gut microbiome with psychoneurological symptoms and gastrointestinal toxicities in gynecologic cancers: a systematic review.

Zahra Amirkhanzadeh Barandouzi1, Claire Rowcliffe2, Julia Schrogin3, Rebecca Meador3, Deborah Watkins Bruner3,4.   

Abstract

INTRODUCTION: Emerging evidence highlights the roles the gut microbiome and the immune system, integral parts of the gut-brain axis, play in developing various symptoms in cancer patients. The purpose of this systematic review was to describe the roles of inflammatory markers and the gut microbiome, as well as to describe their associations with psychoneurological symptoms and gastrointestinal toxicities in women with gynecologic cancers.
METHODS: A comprehensive literature search was conducted in PubMed, Embase, and Web of Science from January 2000 to February 2021. The Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines were utilized to screen the found articles. The quality of the included studies was assessed using the Mixed Method Assessment Tool. In the included studies, various inflammatory markers and gut microbiome diversity and patterns were measured.
RESULTS: Sixteen studies met the eligibility criteria and were included in this systematic review. While there were discrepancies in the associations between various inflammatory markers and symptoms, most of the studies showed positive correlations between interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) and cancer-related psychoneurological symptoms and gastrointestinal toxicities in gynecologic cancer patients. Although there was no consensus in alpha diversity, studies showed significant dissimilarity in the microbial communities (beta diversity) in patients with gastrointestinal toxicities compared with patients without symptoms or healthy controls. Studies also reported inconsistent findings in the abundance of bacteria at different taxonomic levels. Radiation enteritis-derived microbiota could stimulate TNF-α and interleukin 1 beta (IL-1β) secretion.
CONCLUSIONS: Alteration of inflammatory markers, the gut microbiome, and their associations show emerging evidence in the development of psychoneurological symptoms and gastrointestinal toxicities in women with gynecologic cancers. More studies on the interactions between the immune system and the gut microbiome, two integral parts of the gut-brain axis, are required to shed light on the roles they play in symptom development.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Cancer; Gastrointestinal toxicities, Gynecologic cancers; Gut microbiome; Inflammation; Psychoneurological symptoms

Mesh:

Substances:

Year:  2022        PMID: 35396962     DOI: 10.1007/s00520-022-07027-0

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  49 in total

1.  Anxiety and depression after cancer diagnosis: prevalence rates by cancer type, gender, and age.

Authors:  Wolfgang Linden; Andrea Vodermaier; Regina Mackenzie; Duncan Greig
Journal:  J Affect Disord       Date:  2012-06-21       Impact factor: 4.839

2.  Symptom clustering and quality of life in patients with ovarian cancer undergoing chemotherapy.

Authors:  Ju-Hee Nho; Sung Reul Kim; Joo-Hyun Nam
Journal:  Eur J Oncol Nurs       Date:  2017-07-13       Impact factor: 2.398

3.  Patterns and predictors of cancer-related fatigue in ovarian and endometrial cancers: 1-year longitudinal study.

Authors:  Hanneke Poort; Belle H de Rooij; Hajime Uno; Shicheng Weng; Nicole P M Ezendam; Lonneke van de Poll-Franse; Alexi A Wright
Journal:  Cancer       Date:  2020-05-21       Impact factor: 6.860

4.  A longitudinal study on quality of life after gynecologic cancer treatment.

Authors:  Y M Chan; H Y Ngan; B Y Li; A M Yip; T Y Ng; P W Lee; P S Yip; L C Wong
Journal:  Gynecol Oncol       Date:  2001-10       Impact factor: 5.482

5.  Prevalence, demographics, and psychological associations of sleep disruption in patients with cancer: University of Rochester Cancer Center-Community Clinical Oncology Program.

Authors:  Oxana G Palesh; Joseph A Roscoe; Karen M Mustian; Thomas Roth; Josée Savard; Sonia Ancoli-Israel; Charles Heckler; Jason Q Purnell; Michelle C Janelsins; Gary R Morrow
Journal:  J Clin Oncol       Date:  2009-11-23       Impact factor: 44.544

6.  Levels of fatigue compared to levels of cytokines and hemoglobin during pelvic radiotherapy: a pilot study.

Authors:  Karin Ahlberg; Tor Ekman; Fannie Gaston-Johansson
Journal:  Biol Res Nurs       Date:  2004-01       Impact factor: 2.522

Review 7.  Complications of pelvic radiation in patients treated for gynecologic malignancies.

Authors:  Akila N Viswanathan; Larissa J Lee; Jairam R Eswara; Neil S Horowitz; Panagiotis A Konstantinopoulos; Kristina L Mirabeau-Beale; Brent S Rose; Arvind G von Keudell; Jennifer Y Wo
Journal:  Cancer       Date:  2014-07-23       Impact factor: 6.860

8.  Biopsychosocial predictors of pain among women recovering from surgery for endometrial cancer.

Authors:  Kelsey R Honerlaw; Meredith E Rumble; Stephen L Rose; Christopher L Coe; Erin S Costanzo
Journal:  Gynecol Oncol       Date:  2015-09-10       Impact factor: 5.482

9.  When will I feel normal again? Trajectories and predictors of persistent symptoms and poor wellbeing after primary chemotherapy for ovarian cancer.

Authors:  Vanessa L Beesley; Kate Webber; Christina M Nagle; Anna DeFazio; Andreas Obermair; Merran Williams; Michael Friedlander; Penelope M Webb
Journal:  Gynecol Oncol       Date:  2020-08-06       Impact factor: 5.482

10.  Improved survival in ovarian cancer, with widening survival gaps of races and socioeconomic status: a period analysis, 1983-2012.

Authors:  Jinna Wu; Huanhuan Sun; Lewei Yang; Yun Deng; Yan Yan; Shuncong Wang; Guangwei Yang; Haiqing Ma
Journal:  J Cancer       Date:  2018-09-08       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.